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In the hypothalamic arcuate nucleus (ARC), proopiomelanocortin
(POMC) neurons and the POMC-derived peptide α–melanocyte-
stimulating hormone (α-MSH) promote satiety. POMC neurons re-
ceive orexin-A (OX-A)-expressing inputs and express both OX-A
receptor type 1 (OX-1R) and cannabinoid receptor type 1 (CB1R)
on the plasma membrane. OX-A is crucial for the control of wake-
fulness and energy homeostasis and promotes, in OX-1R–expressing
cells, the biosynthesis of the endogenous counterpart of marijuana’s
psychotropic and appetite-inducing component Δ9-tetrahydrocan-
nabinol, i.e., the endocannabinoid 2-arachidonoylglycerol (2-AG),
which acts at CB1R. We report that OX-A/OX-1R signaling at POMC
neurons promotes 2-AG biosynthesis, hyperphagia, and weight gain
by blunting α-MSH production via CB1R-induced and extracellular-
signal-regulated kinase 1/2 activation- and STAT3 inhibition-
mediated suppression of Pomc gene transcription. Because the
systemic pharmacological blockade of OX-1R by SB334867 caused
anorectic effects by reducing food intake and body weight, our re-
sults unravel a previously unsuspected role for OX-A in endocanna-
binoid-mediated promotion of appetite by combining OX-induced
alertness with food seeking. Notably, increased OX-A trafficking
was found in the fibers projecting to the ARC of obese mice (ob/ob
and high-fat diet fed) concurrently with elevation of OX-A release in
the cerebrospinal fluid and blood ofmice. Furthermore, a negative cor-
relation between OX-A and α-MSH serum levels was found in obese
mice as well as in human obese subjects (body mass index > 40),
in combination with elevation of alanine aminotransferase and
γ-glutamyl transferase, two markers of fatty liver disease. These al-
terations were counteracted by antagonism of OX-1R, thus provid-
ing the basis for a therapeutic treatment of these diseases.
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Emerging anatomical, biochemical, and pharmacological evi-dence supports a functional interaction between endo-
cannabinoids and orexin-A (OX-A) (also known as hypocretin-1) in
the hypothalamic regulation of appetite, energy expenditure, and
metabolism (1). In hypothalamic neurons, the endocannabinoid
2-arachidonylglycerol (2-AG) is under the negative control of leptin
(2) and acts through the cannabinoid receptor type 1 (CB1R) to
promote appetite by activating several intracellular pathways, in-
cluding mitogen-activated protein kinases of the extracellular-
signal-regulated kinase (ERK) family (3). OX-A is an orexigenic
neuropeptide expressed by neurons of the lateral hypothalamus
(LH), which acts through the OX-A receptor type 1 (OX-1R) (4).
Activation of OX-1R by OX-A signaling has been found to affect
CB1R function by stimulating 2-AG biosynthesis via the phospho-
lipase C/diacylglycerol lipase α (PLC/DAGL) pathway (5) and by
enhancing ERK1/2 phosphorylation and activity in cells expressing
both OX-1R and CB1R (6, 7). Proopiomelanocortin (POMC)-
containing neurons represent the master subset of hypothalamic
anorexigenic neurons, being the source of the α–melanocyte-
stimulating hormone (α-MSH), which suppresses feeding and/or
stimulates energy expenditure (8–10). Ablation of POMC neu-
rons or loss of α-MSH causes obesity (11, 12), whereas mutations
of the melanocortin 4 receptors (MC4R) for α-MSH are associ-
ated with human obesity (13). POMC neurons receive inhibitory
OX-A inputs that, during rest and sleep periods, suppress hunger
by enhancing firing (14–16), whereas OX-A expression in the LH
is inhibited by α-MSH (17). Notably, marijuana’s psychotropic and
appetite-inducing component, Δ9-tetrahydrocannabinol (THC),
acts at a population of CB1Rs located in the mitochondria of
POMC neurons without affecting α-MSH production (18). Fur-
thermore, the CB1R antagonist rimonabant attenuates the orexigenic
actions of OX-A (19). This evidence suggests the existence of
an OX-A–controlled hypothalamic loop of potential evolutionary
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relevance as it would ensure that alertness is accompanied by food
seeking. However, the molecular mechanism(s) underlying this
pathway remain(s), surprisingly, still unexplored. We have pre-
viously reported that leptin signaling deficiency in obese mice
[both in leptin-knockout ob/ob and high-fat diet (HFD)-fed mice]
causes elevation of 2-AG production and synaptic rewiring to
OX-A neurons with consequent increase of OX-A release to target
areas, including the arcuate nucleus (ARC) (20). Here, we provide
anatomical, molecular, biochemical, and pharmacological evi-
dence that OX-A/OX-1R signaling at POMC neurons in the ARC
reduces POMC and α-MSH production via an autocrine, tran-
scriptional endocannabinoid/ERK/STAT3-mediated mechanism
in sated mice. We further analyzed the potential impact of this
pathway on food intake, body weight, and fatty liver disease in
obese mice and human subjects.
Results
OX-A Expression Is Increased in the ARC of Obese Mice. Hypotha-
lamic leptin signal deficiency in ob/ob and HFD obese mice is
accompanied by increased OX-A immunoreactivity in fibers
projecting to the ARC and enhanced cFos expression in OX-A
neurons of LH (Fig. 1 A and B). CB1Rs are involved in mediating
these effects because 1-h treatment with the CB1R inverse agonist
AM251 (10 mg/kg, i.p.) reduced cFos expression in OX-A
neurons and OX-A immunoreactivity in fibers to the ARC in
both models (Fig. 1 A and B), whereas leptin (5 mg/kg, 2 h i.p.) was
effective in ob/ob, but not in HFD mice (Fig. 1A and SI Appendix,
Fig. S1A), because of hypothalamic leptin insensitivity as previously
shown in this latter model (20). Notably, OX-A immunodensity of
ARC fibers matches with the increase of OX-A release in the ce-
rebrospinal fluid (CSF) of obese mice (Fig. 1C).
OX‐A Drives 2‐AG Biosynthesis in the ARC. The levels of 2-AG were
increased in the ARC of OX-A–injected lean, ob/ob vehicle-injected,
or HFD vehicle-injected mice in comparison with vehicle-injected
lean mice (Fig. 1D). This increase was counteracted by leptin in
ob/ob mice (5 mg/kg; i.p., 1 h; SI Appendix, Fig. S1A) and, in both
models, by (i) antagonism of OX-1R (SB334867, 30 mg/kg; i.p., 1 h;
Fig. 1D) and (ii) inhibition of the 2-AG biosynthetic enzyme,
DAGLα (O-7460; 12 mg/kg; i.p., 1 h; SI Appendix, Fig. S1A). Be-
cause immunolabeling of DAGLα was concentrated in the
somata of POMC neurons and in the neuropil of ARC (SI
Appendix, Fig. S1B), the ARC primary neurons or isolated
primary POMC-eGFP neurons cultured from the ARC POMC-
eGFP heterozygote transgenic mice were tested as a source of
2-AG. Similar to the in vivo situation, OX-A was able to strongly
elevate 2-AG levels in primary neurons in a manner sensitive to
SB334867 and O-7460 (SI Appendix, Table S1). Moreover, a
reduction of phosphatidylinositol 4,5-bisphosphate [PI(4,5)




















































Fig. 1. OX-A increases in the fibers of the ARC of
obese mice enhancing 2-AG biosynthesis. (A) Repre-
sentative coronal sections of similar rostrocaudal po-
sition of the LH and ARC (scale bar: 100 μm) showing
labeled fibers and puncta in the ARC (high magnifi-
cation of the respective boxed area; scale bar: 50 μm)
and cFOS/OX-A costaining in the LH (Insets; scale bar:
100 μm). (B) Bar graphs of OX-A peroxidase-based
optical density (OD, arbitrary units) in the ARC of lean
(light gray bars), ob/ob (black bars), or HFD (dark gray
bars) mice. **P < 0.005 vs. vehicle-injected lean mice;
#P < 0.05 vs. AM251-injected mice. §P < 0.005 vs. leptin-
injected lean mice. (C) OX-A levels in the CSF. (D) 2-AG
levels in the ARC of lean (light gray bars), OX-A–in-
jected lean (orange bars), ob/ob (black bars), or HFD
(dark gray bars) mice reversed by SB334867 treatment.
§P < 0.0005 vs. vehicle-injected lean mice. (E and F)
CB1R and OX-1R immuno-coexpression in POMC neu-
rons. CB1R and OX-1R electron microscopy immuno-
gold detection at the plasma membrane (F) and
postsynaptic side (G) of POMC neurons. CB1R (arrows)
and OX-1R (arrowheads). At, axon terminal; cyt, cyto-
plasm; mitochondria are indicated by the asterisk [scale
bar: 10 μm (E); 0.2 μm (F and G)]. Data are means ±
SEM; n = 6 mice per group fed ad libitum. Statistical
analysis was performed by two-way ANOVA followed
by the Bonferroni post hoc test. (H) Scheme of the
molecular pathway underlying CB1R activation, and
subsequent transcriptional blockade of POMC expres-
sion, via OX-A–induced 2-AG production. 3V, third
ventricle; DAG, diacylglycerol; IP3, inositol triphos-
phate; MEK, mitogen-activated protein kinase; OX1-R,
orexin receptor type-1; PVN, paraventricular nucleus;
Raf-1, protein kinase.
4760 | www.pnas.org/cgi/doi/10.1073/pnas.1521304113 Morello et al.
POMC-eGFP primary neurons [untreated: 108 ± 8.5; OX-A: 60 ±
7.2; OX-A plus SB334867: 90 ± 8.1; SB334867: 95 ± 9.4; PI(4,5)P2
levels are expressed as picomoles per 10,000 cells ± SEM], thus
confirming that OX-A potentiates endocannabinoid signaling via
OX-1R–dependent activation of the PLC/DAGLα-dependent
regulatory pathway.
CB1R and OX-1R Are Coexpressed in POMC Neurons of the ARC. Be-
cause CB1R has been found in a large population of POMC
neurons (18) and our evidence suggests that OX-A might act as an
enhancer of CB1R signaling by promoting 2-AG synthesis, both in
the ARC and in isolated POMC neurons, we analyzed whether
CB1R and OX-1R are colocalized in these neurons. By confocal
and high-resolution electron microscopy, we documented in the
ARC the expression of CB1R in the plasma membrane of 73.4%
(144 of 196) of POMC neurons, where it was coexpressed with OX-
1R in 86.8% (125 of 144) of CB1R/POMC neurons (Fig. 1 E and F).
By electron microscopy immunogold labeling, we revealed CB1R
expression at the postsynaptic side (i.e., postsynaptic density of
boutons) in 22.4% (22 of 98) of POMC neurons (Fig. 1G). Fur-
thermore, CB1R was localized rarely at the presynaptic site of
axosomatic synapses apposed to POMC somata, in agreement with
Hentges (21); rarely at mitochondrial compartments of POMC
neurons, in agreement with Bénard et al. (22) who, in the hippo-
campus, revealed that ∼15% of the CA1 neuronal total CB1R
protein was localized to mitochondria. Notably, the frequency of
CB1R and OX-1R metal particle distribution per micrometer of cell
membrane did not change between obese (OX-1R, n = 4.3 ± 0.6;
CB1R, n = 3.1 ± 0.5) and lean (OX-1R, n = 4.7 ± 0.4; CB1R, n =
3.3 ± 0.4) mice.
OX-A–Induced Hyperphagia in Mice Relies on Inhibition of Neuronal
POMC Expression and α-MSH Production via CB1R Activation and
ERK1/2-Mediated STAT3Ser727 Phosphorylation. It is known that 2-AG
acts through CB1R to promote appetite via potentiation of ERK1/2
activity, which is also the main downstream target for OX-1R
(23–27). We found a strong increase of ERK1/2 phosphorylation/
activation (i.e., of pERK1/2Thr202/Tyr204 levels) in POMC neu-
rons of lean mice following injection of OX-A, and in POMC
neurons of ob/ob and in HFD mice characterized by elevated
OX-A signaling. This effect was (i) antagonized by the CB1R
inverse agonist AM251, and hence possibly due to OX-A–in-
duced 2-AG biosynthesis and CB1R-mediated ERK1/2 phosphory-
lation; (ii) followed by enhancement of STAT3 phosphorylation
at Ser727 without significant change in Tyr705 phosphorylation
(Fig. 2A and SI Appendix, Fig. S2); and (iii) followed by down-
regulation of Pomc gene transcription (Fig. 2B and SI Appendix,
Fig. S3 A–C). These effects were also counteracted by the ERK1/2
inhibitor, PD98059, and SB334867 (Fig. 2 A and B, and SI Ap-
pendix, Figs. S2 and S3 A–C). Interestingly, basal Pomc mRNA
levels of ad libitum fed ob/ob and HFD mice were decreased by 80–
90% in comparison with ad libitum fed lean mice (SI Appendix, Fig.
S3A). This reduction was fully reversed by SB334867 in both ob/ob
and HFD mice (SI Appendix, Fig. S3 B and C). Accordingly, im-
munohistochemistry revealed a decrease of POMC and α-MSH
production in the ARC of lean OX-A–injected, and obese vehicle-
injected, mice. Also, this latter effect was reversed by SB334867
and AM251 (Fig. 2 C–E and SI Appendix, Fig. S3 D and E), as well
by leptin, but only in ob/ob animals (SI Appendix, Fig. S3E) because
of leptin resistance in the ARC of HFD mice (20). Biochemical
analysis of the serum from a cohort of daily OX-A–injected lean
mice revealed a reduction of α-MSH content (Fig. 2F) over 48 h of
treatment with OX-A at doses ineffective on the average immobility-
determined sleep profile (SI Appendix, Fig. S4 and Table S2).
Notably, behavioral analysis of the same cohort of mice revealed a
significant increase in food intake (Fig. 2G) and body weight (Fig.
2H). To confirm that OX-A–mediated reduction of POMC and of
α-MSH production was due to an autocrine effect of 2-AG on
CB1R at the plasma membrane rather than at presynaptic or extra-
ARC populations of CB1Rs, we performed a thorough in vitro study
in primary neurons from the ARC of either wild-type or POMC-
eGFP lean mice. OX-A treatment halved the POMC expression
and α-MSH release, in both types of primary neurons in a manner
prevented by SB334867 or AM251 (SI Appendix, Figs. S5 A–C and
S6A) (α-MSH levels in POMC-eGFP neurons: untreated: 90 ± 4.3;
OX-A: 48.5 ± 5.2; OX-A plus SB334867: 85 ± 6.2; OX-A plus
AM251: 80.5 ± 7.4; values are picograms per milliliter ± SEM). To
exclude possible effects of OX-1R or CB1R agonists/antagonists on
the expression of the corresponding receptors, the mRNA levels of
Cnr1 or Hcrtr1 were shown not to change in primary POMC-
eGFP neurons after treatment with these agonists/antagonists (SI
Appendix, Fig. S6 C and D). To provide further evidence that the
effects of OX-A were due to CB1R activation, experiments were
performed in stabilized mHypoA-POMC/GFP cells transfected with
CB1 receptor-specific siRNA sequences (SI Appendix, Fig. S7A).
We found a ∼50% decrease in CB1R expression with respect to
cells transfected with a scrambled siRNA control (SI Appendix, Fig.
S7B), which in turn displayed levels of CB1R expression identical to
those observed in nontransfected cells. In CB1R siRNA-transfected
cells, OX-A inhibitory effects on both α-MSH production (SI Ap-
pendix, Fig. S7A) or POMC expression (SI Appendix, Fig. S7C) were
greatly reduced, and this lack of effect was not modified by
SB334867 or AM251 (SI Appendix, Fig. S7 A and C). Also, in
mHypoA-POMC/GFP neurons, the levels of Cnr1 or Hcrtr1
mRNA did not change after treatment with the respective se-
lective agonists (arachidonoyl-2-chloroethylamide or OX-A) or
antagonists for the two receptors (SI Appendix, Fig. S7 D and E).
Finally, to determine whether the pharmacological effects of
AM251, OX-A, SB334867, and PD98059 were exerted directly
on ARC (POMC) neurons or indirectly through other circuits,
we compared them following either i.p. or intracerebroventricular
stereotaxic injection in the third ventricle of lean and obese mice
fed ad libitum. No significant difference was found between the
two routes of administration concerning the effect on neuro-
nal POMC expression, α-MSH production, ERK1/2-mediated
STAT3Ser727 or STAT3Tyr705 phosphorylation, and Pomc mRNA
levels (SI Appendix, Fig. S8).
OX-A and α-MSH Plasma Levels Are Inversely Correlated in Severe
Human Obesity. Next, we explored whether higher levels of OX-A
correlate with lower levels of α-MSH in subjects who exhibit clin-
ical markers of obesity. Because a possible correlation between
estrogen and plasma OX-A levels has been described in humans
(28, 29), and a sex difference occurs in the POMC-driven regulation
of energy expenditure and obesity in mice (30), we tested this hy-
pothesis exclusively in male subjects (n = 50) who had suffered from
obesity for at least 5 y in comparison with n = 50 male healthy,
normal-weight, volunteers. Clinical, functional, and biochemical
data were obtained from each patient at the baseline, and secondary
causes of obesity were excluded. No subject was an alcohol abuser
or under pharmacological treatment for any disease. Alanine ami-
notransferase (ALT) and γ-glutamyl transferase (GGT) enzymatic
levels were measured by routine laboratory methods and resulted
significantly higher in obese vs. nonobese men as a reliable hallmark
of fatty liver disease associated with obesity. OX-A serum concen-
trations were significantly higher in obese vs. nonobese men (Fig.
3A). α-MSH serum concentrations were significantly lower in obese
vs. nonobese men (Fig. 3B). Notably, a significant negative corre-
lation was found between the circulating levels of OX-A and
α-MSH (r = −0.778, P < 0.05) in obese subjects, whereas a weak
positive correlation was found in healthy subjects (r = 0.275, P >
0.05) (Fig. 3C). In the serum of the same cohort of obese patients,
negative correlations were also found between: (i) serum levels of
α-MSH and both ALT (r = −0.714, P < 0.05) and GGT (r = −0.828,
P < 0.05); (ii) α-MSH and body mass index (BMI) (r = −0.425,
P < 0.05).








Blocking OX-A Signaling Counteracts Overweight, Hyperphagia, and
Alterations of Hepatosteatosis Markers Associated with Obesity in
Mice. Adult male weight- and age-matched lean (WT and stan-
dard-fat diet fed) and obese mice (both ob/ob and HFD) were
injected with SB334867 for 1 wk (30 mg/kg in lean mice and
60 mg/kg in obese mice, i.p.; n = 2 injections per d, 4 h before
lights off and lights on, respectively) at doses ineffective on sleep
duration (SI Appendix, Fig. S4B and Table S2). This treatment
was able to reduce, in obese mice: (i) the circulating levels of
ALT and GGT to lean control values (Fig. 4A); (ii) macro-
vesicular steatosis, this effect being more evident in HFD mice,
which, after treatment, exhibited almost normal hepatic archi-
tecture and a strong reduction of macrovesicular lipid droplets,
mainly around the portal tract, in comparison with livers from
ob/ob SB334867-treated mice (Fig. 4B); (iii) hepatomegaly (Fig.
4C); (iv) food intake and body weight. In agreement with pre-
vious data (20), the percent food intake reduction by SB334867
was higher in ob/ob than HFD mice, whereas the percent weight
reduction was higher in HFD than in ob/ob mice (Fig. 4D). A
positive correlation was found between the change in body weight
and ALT or GGT circulating levels in ob/ob (r = 0.836, P < 0.05 for
ALT; r = 0.886, P < 0.05 for GGT) and HFD (r = 0.873, P < 0.05
for ALT; r = 0.811, P < 0.05 for GGT) mice, but not in lean mice
(r = 0.101, P > 0.05 for ALT; r = 0.482, P > 0.05 for GGT). Notably,
an elevation of circulating α-MSH to levels comparable to those of
untreated lean mice was found in obese mice after SB334867 or
AM251 treatment (Fig. 4E). Furthermore, a significant correlation
was found between the SB334867-induced increase in α-MSH levels
and the SB334867-induced decrease in the serum levels of ALT or
GGT in the same cohorts of HDF (r = 0.800, P < 0.05 for ALT;
r = 0.859, P < 0.05 for GGT) and ob/ob (r = 0.803, P < 0.05 for
ALT; r = 0.803, P < 0.05 for GGT) mice after 1 wk of treatment
with the antagonist. Taken together, these data establish, at least
in mice, a cause–effect relationship between excessive OX-A levels,
and the consequent impairment of α-MSH production, and some
of the peripheral consequences of hyperphagia and obesity.
Discussion
The present study reveals the existence of a hypothalamic OX-
1R/DAGLα/CB1R loop through which OX-A controls POMC
expression and α-MSH signaling in mice and, possibly, humans.
We report that OX-A–induced and CB1R-mediated STAT3
phosphorylation at Ser-727 by ERK1/2 in lean mice affects nega-
tively the expression of the Pomc gene, thus revealing an un-
precedented endocannabinoid-mediated transcriptional mechanism
through which long-term elevation of OX-A levels stimulates feeding
in a satiety state. We provide evidence that such mechanism, by
being under the negative control of leptin, may also contribute to
obesity and some of its pathological consequences. Because a
possible sex difference occurs in the regulation of plasma OX-A
levels in humans (28,29,31) and in the POMC-driven regulation of
energy expenditure and obesity in mice (30), we performed our
study exclusively in male subjects. In particular, we show that OX-A
acts via DAGLα-catalyzed biosynthesis of 2-AG, which then acts as
an autocrine mediator on OX-1R/CB1R-expressing POMC neu-
rons of the ARC to inhibit STAT3 activity and subsequently re-
press POMC expression and the release of the anorectic peptide,
α-MSH. These direct actions of OX-A were demonstrated in iso-
lated primary POMC neurons and were shown to occur also in vivo
in the ARC of lean mice, where they are enhanced during obesity,
when OX-A/2-AG overactivity correlates with decreased α-MSH
levels and increased BMI and hepatosteatosis. Accordingly,
antagonism of OX-A action at OX-1R does not only counteract
































































































































Relative POMC mRNA levels
Fig. 2. OX-A reduces POMC and α-MSH expression by arresting Pomc gene transcription via the ERK1/2-pSTAT3Ser727 pathway, and causes overweight and
hyperphagia. (A) Representative immunoblots of POMC, ERK1/2, and STAT3 expression in the ARC of vehicle- or OX-A–injected (i.p.) lean mice (6 h for POMC; 1 h for
ERK1/2 or STAT3) pretreated (1 h) with either SB334867, AM251, or PD98059. Fold data represent the means ± SEM from n = 3 mice per group, normalized to the
vehicle-treated group. Dashed lines indicate regions that were cropped. (B) POMCmRNA levels in lean mice normalized to the reference genes Hprt or β-actin; ***P <
0.0005 vs. vehicle-injected mice. (C) POMC and α-MSH immunohistochemical expression in the ARC of vehicle-, OX-A-, SB334867-, or AM251-injected mice. (Scale bar:
100 μm for POMC and 200 μm for α-MSH.) (D and E) Optical density (OD, arbitrary units) of POMC or α-MSH immunoreactivity in lean mice. **P < 0.005 vs. vehicle-
injected mice. Data are means ± SEM from n = 300 ± 30 neurons per treatment. (F) Serum α-MSH levels of vehicle-, OX-A-, SB334867+OX-A-, AM251+OX-A–injected
lean mice. (G and H) The 24- to 48-h OX-A injection increases food intake and body weight in lean mice. *P < 0.05 vs. 24-h vehicle-injected mice; **P < 0.005 vs. 24- or
48-h vehicle-injected mice; #P < 0.05 vs. 24-h OX-A–injected mice. Data are means ± SEM; n = 6 mice per group fed ad libitum. Statistical analysis was run by two-way
ANOVA followed by the Bonferroni post hoc test.
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similarly to what has been found with CB1R antagonists (32), also
reduces hyperphagia, body weight, and steatosis in obese mice. The
finding that OX-A modulates the function of CB1R, for which it
has no significant inherent affinity, by acting on the biosynthesis of
its ligand provides yet another mechanism through which endo-
cannabinoids, which affect food intake in a dual manner (33), exert
hyperphagic actions at hypothalamic CB1R. This finding is also
relevant to the well-established inverse relationship between leptin
and endocannabinoid signaling in obesity, anorexia, or in-
flammatory pain, which is also observed in humans (34, 35). In-
deed, hypothalamic 2-AG levels increase significantly in models of
genetic [ob/ob and db/db mice (2)] or diet-induced (20) leptin
signaling deficiency and obesity, where a significant increase of
OX-A signaling to many target areas, including the ARC, is also
observed (7, 20). In the present study, by reproducing the effect of
leptin deficiency on OX-A levels through the administration of the
exogenous neuropeptide, we provide direct biochemical in vivo
evidence for the occurrence of a stimulatory effect of OX-1R ac-
tivation on 2‐AG biosynthesis in POMC neurons. In lean animals,
OX-A–induced elevation of endocannabinoid tone, and the sub-
sequent reduction of α-MSH levels, may represent a physiological
mechanism ensuring that OX-A–induced alertness is accompanied
by food seeking (17). Accordingly to this physiological function, the
OX-A levels measured in brain dialysates or CSF of rodents peak
late in the active period (36, 37) and, possibly, exhibit a robust time-
dependent fluctuation of the intracellular processing of the pre-
propeptide, and/or transport and release of the peptide from the
somata in the LH to fibers and terminals in the ARC. During
obesity, however, the aberrant activation of OX-A–mediated endo-
cannabinoid signaling at POMC neurons, triggered by deficits in
leptin signaling, creates a vicious circle leading to inhibition of
POMC synthesis, hyperphagia, additional body weight gain, and
hepatosteatosis, as documented by the present findings. Indeed, the
increase in body weight described in OX-A–deficient mice could be
attributed to physical hypoactivity during the light and dark phases
rather than overeating or overdrinking (38). Here, we show that
long-term OX-A overactivity due to lack of leptin signaling con-
tributes to obesity instead via endocannabinoid-mediated suppres-
sion of POMC expression and hyperphagia, because the selective
OX-1R antagonist SB334867 reduced body weight and food intake
at doses ineffective on sleep duration and locomotion. Similarly to
what was found in the periaqueductal gray (7) or in other LH target
areas (20), also in the ARC of ob/ob and HFD-fed mice we found
the increase of OX-A trafficking and release to terminals as well as
the compensatory reduction or no change in the levels of prepro-
OX and OX-A in the LH (20, 39). The present discovery of an
orexin/endocannabinoid/melanocortin interaction, and its impact
on hyperphagia, obesity, and fatty liver, calls for investigations
on potential synergies between OX-1R antagonists and/or CB1R
antagonists and/or MC4R agonists, aiming at counteracting
eating disorders such as binge eating, but also obesity and
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Fig. 3. OX-A and α-MSH levels in the serum of human obese patients are
inversely correlated. (A) The serum median levels of OX-A in obese men are
significantly higher than in nonobese men. Median: 50.75 pg/mL [25%, 75%:
20.45, 26.05] in the group of obese men; median: 23.3 pg/mL [25%, 75%:
42.82, 67.42] in nonobese men; mean ± SD = 55.0 ± 12.8 pg/mL in obese
men; mean ± SD = 23.14 ± 4.4 pg/mL in nonobese men; **P < 0.001 vs.
nonobese men. (B) The serum median levels of α-MSH in obese men are
significantly lower than in nonobese men. Median: 10.75 pmol/L [25%, 75%: 8.4,
12.77] in the group of obese men; median: 21.25 pmol/L [25%, 75%: 19.27,
24.07] in nonobesemen; mean ± SD= 10.52 ± 3.05 pmol/L in obesemen; mean±
SD = 20.93 ± 4.22 pmol/L in nonobese men; **P < 0.001 vs. nonobese men.
(C) The correlation between serum OX-A (in picograms per milliliter) and α-MSH
(in picomoles per liter) levels is weak in nonobese men (r = 0.275) and signifi-
cantly strong in obese men (r = −0.778). Data are from n = 50 male healthy
normal weight (black dots) or obese (black asterisks) volunteers (mean age ± SD,
40.11 ± 2.48 y). The difference between the means of variables measured in
obese and nonobese men was calculated by Mann–Whitney U test. Correlations




Fig. 4. SB334867 treatment counteracts elevation of circulating hepatic
injury markers and reduction of α-MSH levels associated with steatosis and
obesity. (A) SB334867 injection reduces serum ALT and GGT levels (lean, light
gray bars; ob/ob, black bars; HFD, dark gray bars) in obese mice. **P < 0.005
vs. vehicle-injected lean mice; #P < 0.05 vs. SB334867-injected lean mice.
(B) SB334867 injection reduces both size and number of lipid droplets in
obese livers as detected by Oil Red staining. (Scale bar: 60 μm.) (C) Hepa-
tomegaly and pale yellow discoloring in obese mice. (D) SB334867 injection
reduces body weight (lean, light gray bars; ob/ob, black bars; HFD, dark gray
bars) in obese mice. **P < 0.005 vs. vehicle-injected lean mice; *P < 0.05 vs.
SB334867-injected lean mice; #P < 0.05 vs. vehicle-injected ob/ob or HFD
mice. (E) SB334867 or AM251 injection increases serum α-MSH levels in
obese mice. Data are means ± SEM; n = 6 mice per group fed ad libitum.
Statistical analysis was run by two-way ANOVA followed by the Bonferroni
post hoc test.








dysmetabolism, with new safe and effective polypharmaco-
logical or multitarget approaches (40).
Materials and Methods
Animals. Experiments were performed under institutional approval of the
Second University of Naples and according to the guidelines of the in-
stitutional ethical code and the Italian (Decrete Law 116/92) and European
(Official Journal of European Community L358/1 December 18, 1986) regu-
lations for the care and use of laboratory animals.
Immunohistochemistry. Under deep pentobarbital anesthesia, the mice were
perfused transcardially. Brains were cut into 10-μm-thick serial sections in the
coronal plane and processed for immunofluorescence or immunoperoxidase
with specific primary antibodies (see SI Appendix for details).
Lipid Extraction and 2-AG Measurement. Mice were killed by cervical dislo-
cation, the brains removed, and the ARC rapidly dissected. Tissue samples
were pooled and analyzed using liquid chromatography–atmospheric pres-
sure chemical ionization–mass spectrometry as detailed in SI Appendix.
α-MSH and OX-A Measurements. Serum α-MSH or CSF OX-A levels were de-
termined using a commercial ELISA kit according to the manufacturer’s in-
structions (see SI Appendix for details).
Pomc mRNA Quantification. Pomc mRNA was quantified by RT-PCR analysis
using the primers designed by Allele-Id software, version 7.0 (Biosoft In-
ternational), and synthesized (HPLC-purification grade) by MWG-Biotech
(see SI Appendix for details).
Study Population and Hormone Measurements. The study was approved by the
Ethics Committee of the Faculty of Medicine, University of Naples Federico II
(authorization no. 193/06, October 25, 2006; amendment no. 193/06/ESES1,
October 1, 2014), and informed consent was obtained from the subjects. The
study was performed on n = 50 unrelated white young male adults who had
suffered from obesity for at least 5 y. All of the data were compared with
that obtained from 50 male healthy, normal-weight volunteers. Circulating
α-MSH or OX-A levels were measured using an ultrasensitive fluorescent
enzyme immunoassay or an RIA kit, respectively (see SI Appendix for details).
Supplemental methods, along with any additional supplemental data, are
available in SI Appendix; references unique to this section appear only in
SI Appendix.
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